Bortezomib 2mg Injection Mibor

What is Bortezomib 2mg Injection Mibor ?

Bortezomib 2mg Injection Mibor is used in the treatment of multiple myeloma and mantle-cell lymphoma, among other conditions. Its effectiveness is demonstrated by the fact that it stops or slows the proliferation of cancerous cells in the body.

How Mibor is used?

A clinical professional who has been certified administers MIBOR 2MG INJECTION as an intravenous infusion. Your primary care physician (PCP) will assess which portions are necessary and how often they should be consumed. This will differ based on the disease for which you are receiving treatment and may alter over time. You should strictly adhere to your primary care physician’s directions. If you misread it or take too much of it, you may encounter serious side effects. You may not notice or feel the advantages of this drug for several weeks or months, so don’t stop taking it unless your primary care physician tells you to.

Common Side effects of Bortezomib 2mg Injection:

This medicine is associated with one or more of the following symptoms: weakness, nausea, vomiting, and lack of appetite. It’s possible that you’ll be told to drink a lot of liquids on a regular basis during your therapy. While taking medicine, you should avoid driving or using heavy machinery because it may cause tiredness and disorientation. The number of platelets (red blood cells and white platelets) in your blood may drop as a result of this medicine, making you more susceptible to infection. Routine blood tests are required to evaluate platelets, as well as the corrosive levels of uric acid in your heart, liver, and blood. For more details Click Here.

Is bortezomib a type of chemotherapy?

Bortezomib is a proteasome inhibitor, which is a type of cancer treatment medicine. Cells contain proteasomes. They assist in the breakdown of proteins that the cell does not require. Bortezomib inhibits the proteasomes, causing proteins to accumulate inside the cell.

If you are looking for another product or brand click here.